Gershanovich M L, Livshits M E, Antipenkova V I
N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Vopr Onkol. 2000;46(5):604-7.
Combination chemotherapy with hexamethylmelamine (hexalen, altretamine, hexastat), 100 mg, thrice a day, per os, 14 days (out of a 28-day course) and sarcolysin, 15 mg, per os, during the first 5 days of the course, was received by 24 patients with primary advanced tumors of the ovaries, prior to or after cytoreductive surgery. Total apparent response to chemotherapy among 19 patients of the study group was 47.2%, clinically significant (plus stabilization)--94.5%, without significant untoward side-effects (vomiting--19%; leukopenia degree II-III--33% and thrombocytopenia--19%). The drug proved an active component of combination therapy for advanced ovarian carcinoma.
24例原发性晚期卵巢癌患者在减瘤手术前后接受了联合化疗,化疗方案为:六甲蜜胺(hexalen、altretamine、hexastat),每日3次,每次100mg,口服,共14天(28天疗程中的14天);溶肉瘤素,每日15mg,口服,疗程前5天服用。研究组19例患者化疗的总显效为47.2%,临床显著有效(加病情稳定)为94.5%,且无明显不良反应(呕吐——19%;II - III度白细胞减少——33%;血小板减少——19%)。该药物被证明是晚期卵巢癌联合治疗的有效成分。